Cardlytics (NASDAQ:CDLX) posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.31, Morningstar.com reports. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. The firm had revenue of $35.99 million during the quarter, compared to analyst estimates of $36.11 million. During the same period last year, the company earned ($0.35) earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis.
NASDAQ:CDLX traded down $0.32 during trading hours on Friday, hitting $19.78. 172,203 shares of the company’s stock traded hands, compared to its average volume of 205,995. The firm has a market capitalization of $452.97 million, a price-to-earnings ratio of -9.24 and a beta of 3.36. Cardlytics has a 52 week low of $9.80 and a 52 week high of $28.29. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.37 and a current ratio of 2.37.
In related news, CFO David Thomas Evans sold 2,634 shares of Cardlytics stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.42, for a total transaction of $40,616.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kirk Somers sold 2,591 shares of Cardlytics stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $15.67, for a total value of $40,600.97. The disclosure for this sale can be found here. Insiders have sold 22,087 shares of company stock valued at $348,050 in the last three months.
A number of equities analysts have recently commented on the company. Zacks Investment Research raised Cardlytics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Wednesday, March 6th. ValuEngine lowered Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. SunTrust Banks reaffirmed a “buy” rating and issued a $25.00 price target on shares of Cardlytics in a report on Wednesday, March 6th. Finally, KeyCorp raised their price target on Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. Eight research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $22.71.
TRADEMARK VIOLATION NOTICE: “Cardlytics (CDLX) Announces Earnings Results, Beats Estimates By $0.31 EPS” was posted by Rockland Register and is the property of of Rockland Register. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://rocklandregister.com/2019/05/17/cardlytics-cdlx-releases-earnings-results-beats-estimates-by-0-31-eps.html.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.